FY2025 EPS Estimates for AXSM Decreased by Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at Leerink Partnrs dropped their FY2025 EPS estimates for shares of Axsome Therapeutics in a research report issued on Monday, February 10th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($4.60) per share for the year, down from their previous forecast of ($4.30). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.70) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2026 earnings at ($0.40) EPS.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The company had revenue of $104.76 million for the quarter, compared to analysts’ expectations of $98.71 million. During the same period in the prior year, the business earned ($1.32) EPS.

A number of other analysts have also recently weighed in on AXSM. Mizuho raised their price target on shares of Axsome Therapeutics from $137.00 to $195.00 and gave the company an “outperform” rating in a report on Tuesday. Truist Financial raised their price target on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a report on Tuesday. They issued a “buy” rating and a $176.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $190.00 price target on shares of Axsome Therapeutics in a report on Tuesday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $139.00 price target on shares of Axsome Therapeutics in a report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $147.13.

Axsome Therapeutics Stock Up 0.1 %

Shares of Axsome Therapeutics stock opened at $131.68 on Thursday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $134.18. The firm’s 50-day moving average is $96.55 and its two-hundred day moving average is $92.67. The stock has a market cap of $6.38 billion, a price-to-earnings ratio of -20.17 and a beta of 1.05.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently bought and sold shares of AXSM. Creative Planning raised its position in Axsome Therapeutics by 29.8% during the 3rd quarter. Creative Planning now owns 10,854 shares of the company’s stock worth $975,000 after buying an additional 2,489 shares during the last quarter. Values First Advisors Inc. purchased a new position in Axsome Therapeutics during the 3rd quarter worth approximately $568,000. Mirae Asset Global Investments Co. Ltd. raised its position in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after buying an additional 318 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Axsome Therapeutics by 4.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 19,808 shares of the company’s stock worth $1,780,000 after buying an additional 754 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Axsome Therapeutics by 65.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,232 shares of the company’s stock worth $830,000 after buying an additional 3,652 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.